Pozanicline for the treatment of attention-deficit/hyperactivity disorder

Bibliography

• Centers for Disease Control and Prevention (CDC). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR 2010;59(44):1439-43
   PubMedGoogle Scholar
• Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American psychiatric association; Arlington, VA, USA: 2013
   Google Scholar
• Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? a controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010;177(3):299-304
   PubMed Web of Science ®Google Scholar
• Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of ADHD? J Child Psychol Psychiatry 2013;54(1):3-16
   PubMed Web of Science ®Google Scholar
• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   PubMed Web of Science ®Google Scholar
• Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128(5):1007-22
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 2012;21(9):477-92
   PubMed Web of Science ®Google Scholar
• Vyvanse® (lisdexamfetamine dimesylate) capsules, package insert. Shire US, Inc; Wayne, PA: 2013
   Google Scholar
• CONCERTA® (methylphenidate HCl) extended-release tablets package insert. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; Titusville, NJ: 2013
   Google Scholar
• Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 2013;27(12):1081-92
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165(6):721-30
   PubMed Web of Science ®Google Scholar
• Strattera (atomoxetine hydrochloride). US prescribing information. Eli Lilly and Co; Indianapolis, IN: 2014
   Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19(4):353-64
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50(2):171-9
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
   PubMed Web of Science ®Google Scholar
• Intuniv® (guanfacine hydrochloride). US prescribing information. Shire Pharmaceuticals, Inc; Wayne, PA: 2011
   Google Scholar
• KAPVAY (clonidine hydrochloride) extended-release tablets. US prescribing information. GA Shionogi Pharma, Inc; Atlanta: 2013
   Google Scholar
• Levin ED, Conners CK, Silva D, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2001;9(1):83-90
   PubMed Web of Science ®Google Scholar
• Conners CK, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 1996;32(1):67-73
   PubMed Web of Science ®Google Scholar
• Bloem B, Poorthuis RB, Mansvelder HD. Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity. Front Neural Circuits 2014;8:17
   PubMed Web of Science ®Google Scholar
• Muir JL, Everitt BJ, Robbins TW. The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Cereb Cortex 1996;6(3):470-81
   PubMed Web of Science ®Google Scholar
• Bentley P, Driver J, Dolan RJ. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog Neurobiol 2011;94(4):360-88
   PubMed Web of Science ®Google Scholar
• Gill TM, Sarter M, Givens B. Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J Neurosci 2000;20(12):4745-57
   PubMed Web of Science ®Google Scholar
• Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron 2007;56(1):141-54
   PubMed Web of Science ®Google Scholar
• Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007;47:699-729
   PubMed Web of Science ®Google Scholar
• Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004;74(6):363-96
   PubMed Web of Science ®Google Scholar
• Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 2010;40(1-2):211-16
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997;283(1):235-46
   PubMed Web of Science ®Google Scholar
• Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002;163(3-4):362-80
   PubMed Web of Science ®Google Scholar
• Guillem K, Bloem B, Poorthuis RB, et al. Nicotinic acetylcholine receptor beta2 subunits in the medial prefrontal cortex control attention. Science 2011;333(6044):888-91
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. CHANTIX® (varenicline) Tablets, package insert, Pfizer Inc, NY, NY; 2013
   Google Scholar
• Rueter LE, Anderson DJ, Briggs CA, et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 2004;10(2):167-82
   PubMedGoogle Scholar
• Marks MJ, Wageman CR, Grady SR, et al. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. Biochem Pharmacol 2009;78(7):795-802
   PubMed Web of Science ®Google Scholar
• Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006;59(11):1065-70
   PubMed Web of Science ®Google Scholar
• Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 2012;219(3):715-25
   PubMed Web of Science ®Google Scholar
• Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73(6):783-9
   PubMed Web of Science ®Google Scholar
• Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 2011;50(1):73-84.e1
   PubMed Web of Science ®Google Scholar
• Bencherif M, Stachowiak MK, Kucinski AJ, Lippiello PM. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med Hypotheses 2012;78(5):594-600
   PubMed Web of Science ®Google Scholar
• Zurkovsky L, Taylor WD, Newhouse PA. Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics. Biochem Pharmacol 2013;86(8):1133-44
   PubMed Web of Science ®Google Scholar
• Decker MW, Gopalakrishnan M, Meyer MD. The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions. Expert Opin Drug Discov 2008;3(9):1027-40
   PubMed Web of Science ®Google Scholar
• Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999;156(12):1931-7
   PubMed Web of Science ®Google Scholar
• Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184(3-4):523-39
   PubMed Web of Science ®Google Scholar
• Levin ED. Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 2013;86(8):1145-52
   PubMed Web of Science ®Google Scholar
• Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry 2014;75(3):207-14
   PubMed Web of Science ®Google Scholar
• Dunbar GC, Kuchibhatla RV, Lee G. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol 2011;25(8):1020-9
   PubMed Web of Science ®Google Scholar
• Velligan D, Brenner R, Sicuro F, et al. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res 2012;134(1):59-64
   PubMed Web of Science ®Google Scholar
• Mazurov AA, Miao L, Bhatti BS, et al. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective alpha4beta2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. J Med Chem 2012;55(21):9181-94
   PubMed Web of Science ®Google Scholar
• Jucaite A, Ohd J, Potter AS, et al. A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2014;231(6):1251-65
   PubMed Web of Science ®Google Scholar